The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2023 | Updated Phase I study results of PHE885 in patients with R/R multiple myeloma
Nikhil Munshi, MD, Dana-Farber Cancer Institute, Boston, MA, comments on the features and advantages of PHE885, a CAR-T therapy manufactured in less than two days, which allows the product to preserve T-cell stemness. The Phase I study (NCT04318327) reported an overall response rate (ORR) of 98%.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
